Loading
AO
Alphamab Oncology - B Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by XU TING, was filed 23 Jun 2026.
Insider Decl.
35
Thresholds
n/a
Buy Volume
€46M
11 ops. · all time
Sell Volume
€87M
8 ops. · all time
Who traded when
BuySaleCHO Man2 buys4 sales
Liu Yang2 buys2 sales
Xu Ting2 buys
WEI Kevin Cheng1 buy
WU Dong1 buy
Since the insiders bought
- -12.7%Entry HK$7.10 · Close 22 Oct 2026 HK$6.20
- -36.0%Entry HK$9.69 · Close 22 Oct 2026 HK$6.20
- +5.7%Entry HK$7.49 · Close at T+365 HK$7.92
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Alphamab Oncology - B Strong Buy (bullish), based on 1 analysts. Average price target: HK$9.96.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,772 of 26,250 companies
34.1
score / 100
Value28
Quality40
FCF yld-2.3%
Earn yld-1.7%
EV/EBITDA·
ROE-10.0%
Gross mgn89%
Net mgn-20%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$7.05
Analyst consensus
1 analystsStrong buy
HK$9.96Target HK$9.96(+41%)HK$9.96
Income statement
RevenueHK$566.2M
Gross profitHK$502.7M89% margin
EBITDA-HK$41.8M-7% margin
Net income-HK$113.9M-34.0% margin
Valuation
PER (forward)-26.1x
P/Book3.5x
Beta0.55
Balance sheet & cash
Market capHK$6.8B
Total debtHK$123M
Free Cash Flow-HK$153.5M
Debt / Equity16%
Profitability & ownership
ROE-10.0%
ROA-5.5%
% insiders50.3%
% institutions3.2%
Last declaration on 23 June 2026
Declarations35 total
554,000 shares@ HK$7.0223100.0% of flowShareXHKGHKEX:DA20260623E00268
Canonical exit: 2 Sept 2026 (T+90)
554,000 shares@ HK$7.0223100.0% of flowShareXHKGHKEX:DA20260623E00276
Canonical exit: 2 Sept 2026 (T+90)
115,000 shares@ HK$10.1899100.0% of flowShareXHKGHKEX:DA20251124E00447
Canonical exit: 17 Feb 2026 (T+90)
115,000 shares@ HK$10.189923.3% of flowShareXHKGHKEX:DA20251124E00445
Canonical exit: 17 Feb 2026 (T+90)
970,088 sharesShareXHKGHKEX:DA20251030E00463
Canonical exit: 22 Jan 2026 (T+90)
970,088 sharesShareXHKGHKEX:DA20251030E00462
Canonical exit: 22 Jan 2026 (T+90)
413,000 shares@ HK$12.405448.4% of flowShareXHKGHKEX:DA20250918E00514
10,000 shares@ HK$8.680.8% of flowShareXHKGHKEX:DA20250918E00513
10,000 shares@ HK$6.150.7% of flowShareXHKGHKEX:DA20250918E00512
661,000 shares@ HK$7.2920.4% of flowShareXHKGHKEX:DA20250717E00015
661,000 shares@ HK$7.2920.4% of flowShareXHKGHKEX:DA20250717E00014
113,000 shares@ HK$6.75067.2% of flowShareXHKGHKEX:DA20250714E00427
Canonical exit: 12 Oct 2025 (T+90)
14,600,000 shares@ HK$8.0510.0% of flowShareXHKGHKEX:DA20250609E00174
14,600,000 shares@ HK$8.0510.0% of flowShareXHKGHKEX:DA20250609E00192
30,000 sharesShareXHKGHKEX:DA20250603E00055
Canonical exit: 27 Aug 2025 (T+90)
30,000 sharesShareXHKGHKEX:DA20250603E00057
Canonical exit: 27 Aug 2025 (T+90)
60,000 sharesShareXHKGHKEX:DA20250603E00059
Canonical exit: 27 Aug 2025 (T+90)
520,000 shares@ HK$8.460842.9% of flowShareXHKGHKEX:DA20250523E00289
1,040,000 sharesShareXHKGHKEX:DA20241025E00433
314,000,000 sharesShareXHKGHKEX:DA20230426E00236
314,000,000 sharesShareXHKGHKEX:DA20230426E00233
25,000,000 shares@ HK$15.2234.5% of flowShareXHKGHKEX:DA20230210E00316
Canonical exit: 10 May 2023 (T+90)
25,000,000 shares@ HK$15.2234.6% of flowShareXHKGHKEX:DA20230210E00317
Canonical exit: 10 May 2023 (T+90)
25,000,000 shares@ HK$15.2234.0% of flowShareXHKGHKEX:DA20230208E00113
25,000,000 shares@ HK$15.2233.9% of flowShareXHKGHKEX:DA20230208E00128
25 of 35 declarations
About Alphamab Oncology - B
In February 2023, two filings of almost equal size appear in the record of Alphamab Oncology - B: a sale of EUR 44,479,309 by Xu Ting (Director) on February 3, 2023, then a purchase of EUR 45,239,928 by Liu Yang (Director) on February 9, 2023. They are the largest outflow and the largest inflow in the record, apart from Xu Ting's EUR 27,345,558 sale on June 12, 2020 and Liu Yang's EUR 13,077,445 sale on June 5, 2025.
In all, 13 purchases (6 with an amount, EUR 46,438,429, median EUR 278,802) and 9 sales (all with an amount, EUR 87,027,959, median EUR 526,312): 59% purchases on the market side, but heavier sales. On June 4, 2026, Xu Ting and Liu Yang each bought for EUR 427,616.
Read moreShow less
A health care and pharma company listed on the Hong Kong stock exchange, valued at HKD 6.8 billion; 50.3% of the capital is held by filers. Only 5 filers, all Directors, appear, for 31 filings published from December 24, 2019 to June 23, 2026. The year 2025 has 15, and on May 29, 2025 three directors bought on the same day. The six filings of the last twelve months are all purchases. Median publication delay: 5 days.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
